Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...